At Lilly, Paul helped develop the company’s mental health blockbusters, Zyprexa and Cymbalta, and helped oversee development of muscarinic cholinergic receptor agonist xanomeline, where its ...

The US regulator has cleared the combination of muscarinic M1 and M4 ... entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way ...

The primary goal of the trial is to measure the decrease in the Positive and Negative Syndrome Scale from baseline.

making it is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors.